Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology
Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk, Pietro Scicchitano, Francesco Massari · 2024
Read Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology by Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk, Pietro Scicchitano, Francesco Massari (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11727519.txt.
Description
Ewelina Młynarska and co-authors review hypertrophic cardiomyopathy, a thickened heart muscle condition affecting millions, with a spotlight on the drug mavacamten. The disease springs from over-eager actomyosin interactions: the heart's motor proteins grab too much, wasting energy and stiffening relaxation. Genes, age, and other illnesses steer its course.
Mavacamten dials the motor down, reducing the number of myosin heads available to form cross-bridges. The review covers how diagnosis has grown from simple ultrasound to imaging, genetics, and biomarkers, then weighs the drug's evidence and prospects. A targeted pill for a once untreatable mechanics problem marks a turning point cardiology is still absorbing.
Catalog record
| CREATOR | Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk, Pietro Scicchitano, Francesco Massari |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |